AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35429901 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 601
Study 35429901 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 601
Study 35429901 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 601
Study 35429901 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus ET
Number of subjects: 601
Study 34264157 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-PET-MRI
Number of subjects: 153
Study 34264157 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-MRI
Number of subjects: 153
Study 34264157 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-PET
Number of subjects: 153
Study 34264157 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-MRI
Number of subjects: 153
Study 34264157 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of three bi-modality combinations (CT-PET, CT-MRI, PET-MRI)
Number of subjects: 153
Study 32522024 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal acupuncturists providing yoga or Tai Chi classes
Number of subjects: 0
Study 32522024 — intervention group
Group type: COMPARATOR
Intervention: Community acupuncturists
Number of subjects: 0
Study 32522024 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal opioid utilization
Number of subjects: 0
Study 32522024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity levels
Number of subjects: 0
Study 32522024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0
Study 35546527 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus regimen (low dose CNI, everolimus, and prednisolone)
Number of subjects: 54
Study 35546527 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive regimen (CNI, mycophenolate mofetil, and prednisolone)
Number of subjects: 54
Study 34164123 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio health/nutrition education
Number of subjects: 712
Study 34164123 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 712
Study 35119460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of visual campaign and narrative vignette from the perspective of a patient with OUD
Number of subjects: 1842
Study 35119460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined visual campaign and patient vignette about the value of medication treatment for OUD
Number of subjects: 1842
Study 34520219 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD consolidation (bortezomib, lenalidomide, and dexamethasone)
Number of subjects: 878
Study 34520219 — intervention group
Group type: COMPARATOR
Intervention: No consolidation
Number of subjects: 878
Study 34520219 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD consolidation
Number of subjects: 878
Study 34520219 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD consolidation including maintenance
Number of subjects: 878
Study 34520219 — intervention group
Group type: COMPARATOR
Intervention: No consolidation including maintenance
Number of subjects: 878
Study 34520219 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD treatment
Number of subjects: 878
Study 32799981 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions for children under five years
Number of subjects: 4125
Study 35197337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM devices with sensors and solar chargers
Number of subjects: 50
Study 35197337 — intervention group
Group type: COMPARATOR
Intervention: Safe‐Accu home glucose metres and logbooks
Number of subjects: 50
Study 33409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cryoneurolysis of splanchnic nerves
Number of subjects: 5
Study 34907041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE)
Number of subjects: 200
Study 34907041 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive internal medical treatment (as part of the trial group)
Number of subjects: 200
Study 34907041 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive internal medical treatment (control group)
Number of subjects: 200
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anemia prevalence
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia prevalence
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate anemia prevalence
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia prevalence
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk of overall anemia
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk of mild anemia
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk of moderate/severe anemia
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased risk of moderate/severe anemia
Number of subjects: 5229
Study 32576157 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective factor for overall, mild and moderate/severe anemia
Number of subjects: 5229
Study 34991130 — intervention group
Group type: EXPERIMENTAL
Intervention: Zishen Yutai Pill
Number of subjects: 2265
Study 34991130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2265
Study 34496544 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (n=96) including 51 OSCC patients and 45 healthy subjects
Number of subjects: 76
Study 34496544 — intervention group
Group type: EXPERIMENTAL
Intervention: Verification group (n=50) including 25 OSCC patients and 25 healthy individuals
Number of subjects: 76
Study 34496544 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic panel
Number of subjects: 76
Study 34496544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 76
Study 32340780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 32340780 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (general reference)
Number of subjects: 0
Study 34344250 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual training
Number of subjects: 121
Study 34344250 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual rotation training
Number of subjects: 121
Study 34344250 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual training without rotational movement
Number of subjects: 121
Study 34228127 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus nicotine replacement therapy (NRT)
Number of subjects: 46
Study 34228127 — intervention group
Group type: COMPARATOR
Intervention: Brief health education (BHE)
Number of subjects: 46
Study 32213121 — intervention group
Group type: COMPARATOR
Intervention: Modified Paleolithic diet (Paleo; n=6)
Number of subjects: 15
Study 32213121 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT)‐based ketogenic diet (Keto; n=5)
Number of subjects: 15
Study 32213121 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control; n=4)
Number of subjects: 15
Study 32857992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 + 1 dosing schedule of PCV13 (6w + 1 and 14w + 1 groups)
Number of subjects: 600
Study 32857992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 + 1 dosing schedule of PCV10 (6w + 1 and 14w + 1 groups)
Number of subjects: 600
Study 32857992 — intervention group
Group type: COMPARATOR
Intervention: 2 + 1 dosing schedule of PCV13
Number of subjects: 600
Study 32857992 — intervention group
Group type: COMPARATOR
Intervention: 2 + 1 dosing schedule of PCV10
Number of subjects: 600
Study 32857992 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 600
Study 35260448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Nutrition Therapy
Number of subjects: 240
Study 35260448 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 240
Study 32513192 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-forming interventions (e.g., having a relative ask about pill-taking, re-packaging medications, leaving medications in view, using alarms, carrying water, linking pill-taking to radio/prayer schedules)
Number of subjects: 42
Study 32513192 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine habits (eating, bathing, sleeping)
Number of subjects: 42
Study 36129711 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture for 8 weeks
Number of subjects: 70
Study 36129711 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture for 8 weeks
Number of subjects: 70
Study 33663237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 464
Study 33663237 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 464
Study 32785689 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 95
Study 33891348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg)
Number of subjects: 219
Study 33891348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675/225/225 mg)
Number of subjects: 219
Study 33891348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 33891348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 219
Study 33206751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil combined with tacrolimus (Group A)
Number of subjects: 234
Study 33206751 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil combined with cyclophosphamide (Group B)
Number of subjects: 234
Study 34524005 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 0
Study 34524005 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 0
Study 33849494 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of oat bran daily for 4 weeks at lunch and dinner
Number of subjects: 112
Study 33849494 — intervention group
Group type: COMPARATOR
Intervention: Standard diet for gestational diabetes (control group)
Number of subjects: 112
Study 32296094 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpatch Serum
Number of subjects: 180
Study 32296094 — intervention group
Group type: COMPARATOR
Intervention: Compeed Patches
Number of subjects: 180
Study 32296094 — intervention group
Group type: COMPARATOR
Intervention: Zovirax Cream (5% acyclovir)
Number of subjects: 180
Study 35365344 — intervention group
Group type: EXPERIMENTAL
Intervention: CARD (Comfort Ask Relax Distract) system
Number of subjects: 1919
Study 35365344 — intervention group
Group type: COMPARATOR
Intervention: Control (usual practices)
Number of subjects: 1919
Study 34463746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hazard removal intervention delivered by an occupational therapist over 2 weeks with a 6-month booster.
Number of subjects: 310
Study 34463746 — intervention group
Group type: COMPARATOR
Intervention: Usual care control consisting of annual assessments and community referral.
Number of subjects: 310
Study 34463746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hazard removal intervention
Number of subjects: 310
Study 33037518 — intervention group
Group type: EXPERIMENTAL
Intervention: Getong Tongluo Capsule (GTC) 250 mg plus EGB-matching placebo 40 mg (GTC group)
Number of subjects: 477
Study 33037518 — intervention group
Group type: EXPERIMENTAL
Intervention: EGB 40 mg plus GTC-matching placebo 250 mg (EGB group)
Number of subjects: 477
Study 33037518 — intervention group
Group type: COMPARATOR
Intervention: GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg (Placebo group)
Number of subjects: 477
Study 33037518 — intervention group
Group type: EXPERIMENTAL
Intervention: Getong Tongluo Capsule (GTC) 250 mg
Number of subjects: 477
Study 33037518 — intervention group
Group type: EXPERIMENTAL
Intervention: EGB 40 mg
Number of subjects: 477
Study 35932550 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat conditioning (CS+ and CS-)
Number of subjects: 81
Study 35932550 — intervention group
Group type: COMPARATOR
Intervention: Supportive social interaction
Number of subjects: 81
Study 35932550 — intervention group
Group type: COMPARATOR
Intervention: Unsupportive social interaction
Number of subjects: 81
Study 35932550 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year follow-up
Number of subjects: 81
Study 33078961 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback system (AFS) during practice installation
Number of subjects: 60
Study 33078961 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard printed instruction manuals
Number of subjects: 60
Study 35629000 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-disgust cognitive behavioral therapy (AD-CBT)
Number of subjects: 55
Study 35629000 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) alone
Number of subjects: 55
Study 32716603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigator with 0.06% CHX solution
Number of subjects: 60
Study 32716603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigator with water
Number of subjects: 60
Study 32716603 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene instruction and mechanical debridement)
Number of subjects: 60
Study 32716603 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 60
Study 36460991 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS Fighter · Health Defense (game-based health education)
Number of subjects: 0
Study 33113956 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglena intake
Number of subjects: 0
Study 33113956 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 0
Study 35180612 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT+MBI
Number of subjects: 36
Study 35180612 — intervention group
Group type: COMPARATOR
Intervention: IRT
Number of subjects: 36
Study 36482026 — intervention group
Group type: COMPARATOR
Intervention: Cathodal t-DCS
Number of subjects: 21
Study 36482026 — intervention group
Group type: COMPARATOR
Intervention: Anodal t-DCS
Number of subjects: 21
Study 33431252 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) implementation
Number of subjects: 147
Study 33431252 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to POCT implementation
Number of subjects: 147
Study 33431252 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivators for POCT implementation
Number of subjects: 147
Study 33874643 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball exercise group (n=30)
Number of subjects: 60
Study 33874643 — intervention group
Group type: COMPARATOR
Intervention: Stretching group (n=30)
Number of subjects: 60
Study 32016292 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib, 200 mg
Number of subjects: 0
Study 32016292 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib, 100 mg
Number of subjects: 0
Study 32016292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34952989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation (CTR) program for 10 months
Number of subjects: 67
Study 34952989 — intervention group
Group type: COMPARATOR
Intervention: Center-based cardiac rehabilitation (CBCR) program for 8 weeks
Number of subjects: 67
Study 32507154 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception training without visual input
Number of subjects: 20
Study 32507154 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 36098384 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° left operating table tilt
Number of subjects: 100
Study 36098384 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 100
Study 33863272 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 838
Study 33863272 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 838
Study 32893384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng, Lilii Bulbus and Poria (GLP) supplementation
Number of subjects: 120
Study 34236303 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg phentermine
Number of subjects: 932
Study 34236303 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg phentermine
Number of subjects: 932
Study 34236303 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg and 30 mg phentermine
Number of subjects: 932
Study 33743794 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (exemption of gluten, dairy, sugar, and ultra-processed foods) for 3 months, with a low FODMAP diet in the first month and reintroduction of fruits and vegetables over 2 months.
Number of subjects: 100
Study 33743794 — intervention group
Group type: COMPARATOR
Intervention: General recommendations for healthy eating (control group).
Number of subjects: 100
Study 34802945 — intervention group
Group type: EXPERIMENTAL
Intervention: High LACE index score
Number of subjects: 88
Study 34802945 — intervention group
Group type: COMPARATOR
Intervention: Low-to-moderate LACE index score
Number of subjects: 88
Study 33299099 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented blood sucrose
Number of subjects: 0
Study 33299099 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood fructose
Number of subjects: 0
Study 32444201 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided acromioplasty (GA)
Number of subjects: 64
Study 32444201 — intervention group
Group type: COMPARATOR
Intervention: Freehand acromioplasty (FA)
Number of subjects: 64
Study 32444201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GA and FA
Number of subjects: 64
Study 33478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple low-dose antihypertensive drug combination
Number of subjects: 1268
Study 33478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual drug combination
Number of subjects: 1268
Study 33478567 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (monotherapy followed by dual treatment)
Number of subjects: 1268
Study 33478567 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with optional dose titration after 4 and 8 weeks
Number of subjects: 1268
Study 33478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical manifestations of end-organ damage
Number of subjects: 1268
Study 33478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 1268
Study 34172326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND)
Number of subjects: 40
Study 34172326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 34182929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (pre-operative acetaminophen and gabapentin, intra-operative flurbiprofen and ropivacaine, post-operative acetaminophen and celecoxib)
Number of subjects: 140
Study 34182929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 140
Study 34182929 — intervention group
Group type: COMPARATOR
Intervention: Conventional opioid‐based analgesia
Number of subjects: 140
Study 35420672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib added to decitabine therapy
Number of subjects: 96
Study 35420672 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence in instrumental activities of daily living
Number of subjects: 96
Study 35420672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 96
Study 33849006 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming exercise (60 min swimming/day, 6 days per week, for 8 weeks)
Number of subjects: 16
Study 33849006 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming exercise
Number of subjects: 16
Study 33849006 — intervention group
Group type: COMPARATOR
Intervention: Sedentary normotensive group (WKY)
Number of subjects: 16
Study 32546493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Exercise Rehabilitation Management System (IERMS) with usual care for the first 6 weeks
Number of subjects: 70
Study 32546493 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 32546493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Exercise Rehabilitation Management System (IERMS)
Number of subjects: 70
Study 34883269 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 172
Study 34883269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study 34540187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced CIK cells
Number of subjects: 20
Study 34540187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 34224192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 29
Study 32679201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow treatment
Number of subjects: 363
Study 35650612 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Gyejibokryeong-hwan (GBH)
Number of subjects: 126
Study 35650612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Gyejibokryeong-hwan (GBH)
Number of subjects: 126
Study 35650612 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 126
Study 34275552 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed practice protocol (1 session/day)
Number of subjects: 10
Study 34275552 — intervention group
Group type: COMPARATOR
Intervention: Mass practice protocol (6 sessions/day)
Number of subjects: 10
Study 32217561 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin 500 mg one time per day for 3 days
Number of subjects: 400
Study 32217561 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin 1 g three times per day for 5 days
Number of subjects: 400
Study 32217561 — intervention group
Group type: COMPARATOR
Intervention: standard-of-care (no immediate antibiotic)
Number of subjects: 400
Study 32217561 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin and amoxicillin (combined)
Number of subjects: 400
Study 33892154 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 274